Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients
- 27 March 2019
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 48 (1) , 125-133
Abstract
The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, PROTECHT, CONKO, and ONKOTEV scores for the first 3–6 months and for 12 months, and re-assessed scores after 3–6 months to determine the influence of variations in patients’ risk classification on performance. Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first or new line of chemotherapy. The primary outcome was symptomatic or incidental VTE. A total of 776 patients were included of whom 540 (70%) had distant metastases. The time-dependent c-statistics of Khorana, PROTECHT, CONKO, and ONKOTEV scores at 6 months were 0.61 (95% CI 0.56 to 0.66), 0.61 (95% CI 0.55 to 0.66), 0.60 (95% CI 0.54 to 0.66), and 0.59 (0.52 to 0.66), respectively, with a tendency to decrease during follow-up. None of the scores discriminated between high and low risk patients at the conventional 3-point positivity threshold. The use of a 2-point positivity threshold improved performance of all scores and captured a higher proportion of VTE. The accuracy of risk scores re-assessed at 3–6 months was modest. The Khorana, PROTECHT, CONKO, and ONKOTEV scores are not sufficiently accurate when used at a conventional threshold of 3 points. Performance improves at positivity threshold of 2 points, as evaluated in recent randomized studies on VTE prophylaxis. Score accuracy tends to decrease over time suggesting the need of periodic re-evaluation to estimate possible variation of risk.Keywords
This publication has 19 references indexed in Scilit:
- Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2015
- Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 TrialJournal of Clinical Oncology, 2015
- Biomarkers for prediction of venous thromboembolism in cancerBlood, 2013
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Incidental venous thromboembolism in oncology patientsJournal of Thrombosis and Haemostasis, 2012
- A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht scoreInternal and Emergency Medicine, 2012
- Prediction of venous thromboembolism in cancer patientsBlood, 2010
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational studyCancer, 2005
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005